It works by switching off nociceptors in the peripheral nervous system, and therefore preventing pain signals getting to the brain. This represents a potential new breakthrough in a world which has ...

Experts discuss the current research on the use of digital therapeutics for managing chronic pain in rheumatic disease.

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.